References
- TormoMMaruganICalabuigMMyelodysplastic syndromes: an update on molecular pathologyClin Transl Oncol2010121065266120947479
- OrnsteinMCMukherjeeSSekeresMAMore is better: combination therapies for myelodysplastic syndromesBest Pract Res Clin Haematol2015281223125659727
- LvLLinGGaoXCase-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese populationAm J Hematol201186216316921264898
- KuangSLiangWClinical analysis of 43 cases of chronic benzene poisoningChem Biol Interact200515315412913516289500
- KuendgenALubbertMCurrent status of epigenetic treatment in myelodysplastic syndromesAnn Hematol200887860161118392623
- NavadaSCSteinmannJLubbertMSilvermanLRClinical development of demethylating agents in hematologyJ Clin Invest20141241404624382388
- KellyTKDe CarvalhoDDJonesPAEpigenetic modifications as therapeutic targetsNat Biotechnol201028101069107820944599
- CashenAFSchillerGJO’DonnellMRDiPersioJFMulticenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemiaJ Clin Oncol201028455656120026803
- WeeSDhanakDLiHTargeting epigenetic regulators for cancer therapyAnn N Y Acad Sci20141309303624571255
- HaladynaJNYamauchiTNeffTBerntKMEpigenetic modifiers in normal and malignant hematopoiesisEpigenomics20157230132025942537
- JuoYYGongXJMishraAEpigenetic therapy for solid tumors: from bench science to clinical trialsEpigenomics20157221523525942532
- AzadNZahnowCARudinCMBaylinSBThe future of epigenetic therapy in solid tumours – lessons from the pastNat Rev Clin Oncol201310525626623546521
- HuangYWKuoCTStonerKHuangTHWangLSAn overview of epigenetics and chemopreventionFEBS Lett2011585132129213621056563
- BejarRSteensmaDPRecent developments in myelodysplastic syndromesBlood2014124182793280325237199
- EstephanFTiuRVCurrent and novel therapeutic approaches in myelodysplastic syndromesJ Community Support Oncol201412723624925830232
- IshikawaTNovel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndromeInt J Clin Oncol2014191101524357411
- GurionRVidalLGafter-GviliA5-azacitidine prolongs overall survival in patients with myelodysplastic syndrome – a systematic review and meta-analysisHaematologica201095230331019773261
- XieMJiangQXieYComparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participantsClin Lymphoma Myeloma Leuk2015151222825042977
- XuJZhouYZhangJHigh incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutationClin Chim Acta201241315–161284128722546611
- SugiyamaEKaniwaNKimSRPharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphismJ Clin Oncol2007251324217194903
- IyerSNAnkalaASinghalRSHegdeMRDetermination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic populationGene20135241353923612254
- EbrahemQMahfouzRZNgKPSaunthararajahYHigh cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effectsOncotarget20123101137114523087155
- MahfouzRZJankowskaAEbrahemQIncreased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapyClin Cancer Res201319493894823287564
- LeeYGKimIYoonSSComparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromesBr J Haematol2013161333934723432512
- OkiYKondoYYamamotoKPhase I/II study of decitabine in patients with myelodysplastic syndrome: a multi-center study in JapanCancer Sci2012103101839184722816487
- UchidaTOgawaYKobayashiYPhase I and II study of azacitidine in Japanese patients with myelodysplastic syndromesCancer Sci201110291680168621624006
- MusolinoCSant’antonioEPennaGEpigenetic therapy in myelodysplastic syndromesEur J Haematol201084646347320192987
- SantosFPKantarjianHGarcia-ManeroGIssaJPRavandiFDecitabine in the treatment of myelodysplastic syndromesExpert Rev Anticancer Ther201010192220014881
- BryanJKantarjianHGarcia-ManeroGJabbourEPharmacokinetic evaluation of decitabine for the treatment of leukemiaExpert Opin Drug Metab Toxicol20117566167221500965
- SaunthararajahYSekeresMAdvaniAEvaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromesJ Clin Invest201512531043105525621498
- MomparlerRLPharmacology of 5-aza-2′-deoxycytidine (decitabine)Semin Hematol2005423 Suppl 2S9S1616015507
- SeymourJFFenauxPSilvermanLREffects of azacitidine compared with conventional care regimens in elderly (>/=75 years) patients with higher-risk myelodysplastic syndromesCrit Rev Oncol Hematol201076321822720451404
- FenauxPMuftiGJHellstrom-LindbergEEfficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III studyLancet Oncol200910322323219230772
- ChristiansenDHAndersenMKPedersen-BjergaardJMethylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemiaLeukemia20031791813181912970781
- KantarjianHIssaJPRosenfeldCSDecitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized studyCancer200610681794180316532500
- LubbertMWijermansPKunzmannRCytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′-deoxycytidineBr J Haematol2001114234935711529854
- WijermansPLubbertMVerhoefGLow-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patientsJ Clin Oncol200018595696210694544
- SabaHRosenfeldCIssaJPFirst report of the phase III North American trial of decitabine in advanced myelodysplastic syndrome (MDS)Blood200410423a
- YeeKWJabbourEKantarjianHMGilesFJClinical experience with decitabine in North American patients with myelodysplastic syndromeAnn Hematol200584Suppl 1182416273408
- van den BoschJLubbertMVerhoefGWijermansPWThe effects of 5-aza-2′-deoxycytidine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromesLeuk Res200428878579015203276
- SabaHLubbertMWijermansPWResponse rates of phase 2 and phase 3 trials of decitabine (DAC) in patients with myelodysplastic syndromes (MDS)Blood2005106706a15802527
- HuQJChenBARecent advances in therapy of myelodysplastic syndromesZhongguo Shi Yan Xue Ye Xue Za Zhi20122061522152523257466
- VisconteVTiuRVRogersHJPathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the diseaseBlood res201449421622725548754
- LiJChenYZhuYEfficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaOncotarget2015686448645825749041
- GreenbergPLAttarEBennettJMNCCN clinical practice guidelines in oncology: myelodysplastic syndromesJ Natl Compr Canc Netw201191305621233243
- XiaoZDecitabine in myelodysplastic syndromes: the current status and futureZhonghua Xue Ye Xue Za Zhi201435318518624666480
- LvZClinical efficacy of low-dose demethylation treatment of myelodysplastic syndromeMudanjiang Yi Xue Yuan Xue Bao20143534748
- YangHZhuHYJiangMMClinical observation of decitabine-treating patients with myelodysplastic syndrome and acute myeloid leukemiaZhongguo Shi Yan Xue Ye Xue Za Zhi201321112112523484704
- WangHWuYGeSLiuXTherapeutic effect of decitabine in treating middle and high risk myelodysplastic syndromeZhi Ye Wei Sheng Yu Bing Shang2014292108110
- CaoHWangZLuXZSWuZClinical research of patients with myelodysplastic syndromes and acute myeloid leukemia treated by decitabine with half quantity of CAG/CAOZhongguo Yi Xue Chuang Xin20141131131133
- ZhangXDengYZhangLFour case reports of sequential regimen of decitabine followed by half standard dose CAG in myelodysplastic syndrome and leukemic transformationBai Xi Bao Lin Ba Liu2012217433435
- GuanJJiangYSunAEffect of decitabine in combination with HAG/IAG regimen on elderly patients with AML and higher-risk MDSZhong Hua Lin Chuang Yi Shi Za Zhi201482138973900 Chinese
- ChenQZhaoLLingCEfficacy and safety of demethylation agents for middle/high-risk patients with myelodysplastic syndrome: a systematic reviewZhongguo Xun Zheng Yi Xue Za Zhi201414910971103
- YangBCaiLWangHTreatment of an elderly patient with acute myelocytic leukemia transformed from myelodysplastic syndrome with decitabine in ultra-low dosage combining with transfusion of autologous cytokineinduced killer cells: a case report and review of literatureJie Fang Jun Yi Xue Za Zhi2014394315319
- XiaoYFengJResearch progress of traditional Chinese Medicine on myelodysplastic syndromeZhong Yi Yao Xin Xi20052241719
- WuHPractical Traditional Chinese Hematology2nd edShanghai, People’s Republic of ChinaShanghai University of Traditional Chinese Medicine Press1996
- HuangZQiuZChenPChinese medicine treatment of MDS staging clinical experienceZhong Yi Wen Xian Za Zhi20072533335
- SunWMengXAdvances in the combined treatment of myelodysplastic syndrome with traditional Chinese and western medicineZhong Yi Yao Xin Xi20072461214
- ZhangHMaJComparison of traditional Chinese and western medicine treatment of myelodysplastic syndromeZhongguo Xian Dai Yi Sheng200846217185
- ZhuXQiuZChenPZhaoLHuangZHuXClinical efficacy of chinese medicine combined with decitabine in treatment of high risk myelodysplastic syndromesZhong Hua Zhong Yi Yao Xue Kan201432512401243